StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2023 - 02 - 28
1
2023 - 01 - 18
1
2022 - 03 - 07
1
2021 - 11 - 24
1
2021 - 11 - 01
1
2021 - 09 - 20
1
2021 - 09 - 08
1
2021 - 07 - 28
2
2021 - 07 - 13
1
2021 - 06 - 22
1
Sector
Health technology
11
Tags
Agreement
1
Cancer
5
Cell carcinoma
1
China
5
Commercialization
1
Drug
1
Endocrine
1
Lung cancer
4
Milestone
2
N/a
11
One
1
Orpathys
3
Renal
1
Results
2
Star
1
Therapy
2
Trial
4
Year
1
Entities
3m company
13
Abbott laboratories
82
Abbvie inc.
100
Adaptimmune therapeutics plc
4
Agilent technologies, inc.
4
Alkermes plc
5
Amgen inc.
106
Aptargroup, inc.
6
Artelo biosciences, inc.
17
Astellas pharma inc
42
Astrazeneca plc
664
Avenue therapeutics, inc.
7
Aveo pharmaceuticals, inc.
6
Bausch health companies inc.
12
Baxter international inc.
27
Becton, dickinson and company
7
Biogen inc.
22
Biomarin pharmaceutical inc.
4
Biontech se
8
Boston scientific corporation
5
Bristol-myers squibb company
61
Checkpoint therapeutics, inc.
5
Compugen ltd.
7
Csl ltd
14
Eli lilly and company
97
Endo international plc
9
Fibrogen, inc
4
Fortress biotech, inc.
31
Fusion pharmaceuticals inc.
4
Galapagos nv
8
Genprex, inc.
9
Gilead sciences, inc.
10
Glaxosmithkline plc
189
Hutchison china meditech limited
11
Illumina, inc.
7
Innate pharma s.a.
4
Innate pharma sa
4
Insulet corporation
4
Ionis pharmaceuticals, inc.
4
Jazz pharmaceuticals plc
5
Johnson & johnson
117
Journey medical corp
6
Koninklijke philips n.v.
11
Medtronic plc
14
Mitsubishi chemical holdings corp
5
Moderna, inc.
5
Mustang bio, inc.
6
Neurocrine biosciences, inc.
5
Novartis ag
198
Novo nordisk a/s
29
Pfizer, inc.
45
Puma biotechnology inc
6
Reckitt benckiser group plc
5
Regeneron pharmaceuticals, inc.
5
Sanofi
213
Takeda pharmaceutical company limited
29
Teva pharmaceutical industries limited
7
Teva pharmaceutical industries ltd
85
Thermo fisher scientific inc
19
Viatris inc.
32
Symbols
AZN
11
AZNCF
4
BGNE
7
CG
1
EPZM
4
HCM
107
LLY
11
MS
3
SNY
1
SNYNF
1
TAK
7
Exchanges
Nasdaq
11
Nyse
2
Crawled Date
2023 - 02 - 28
1
2023 - 01 - 18
1
2022 - 03 - 07
1
2021 - 11 - 24
1
2021 - 11 - 01
1
2021 - 09 - 20
1
2021 - 09 - 08
1
2021 - 07 - 28
2
2021 - 07 - 13
1
2021 - 06 - 22
1
Crawled Time
01:00
3
05:00
1
06:00
1
07:00
1
09:00
1
11:00
1
12:00
1
15:00
1
18:00
1
Source
www.globenewswire.com
11
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Hutchison china meditech limited
symbols :
Azn
save search
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Published:
2023-02-28
(Crawled : 09:00)
- globenewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
-0.01%
|
O:
-3.3%
H:
0.0%
C:
-1.25%
LLY
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
135.85%
|
O:
-0.36%
H:
0.0%
C:
-1.35%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
6.17%
|
O:
5.03%
H:
2.91%
C:
0.3%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
2.19%
|
O:
-1.65%
H:
0.58%
C:
-0.79%
year
results
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Published:
2023-01-18
(Crawled : 15:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
0.12%
|
O:
1.32%
H:
4.49%
C:
1.01%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
-3.5%
|
O:
1.36%
H:
0.33%
C:
-1.13%
orpathys
drug
agreement
china
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Published:
2022-03-07
(Crawled : 05:00)
- globenewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
19.49%
|
O:
2.76%
H:
0.0%
C:
-1.8%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-26.97%
|
O:
-10.68%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
17.86%
|
O:
-1.33%
H:
0.0%
C:
0.0%
orpathys
star
lung cancer
one
cancer
milestone
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published:
2021-11-24
(Crawled : 01:00)
- globenewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
20.54%
|
O:
-0.02%
H:
1.33%
C:
1.33%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-50.85%
|
O:
-4.39%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
21.17%
|
O:
-0.07%
H:
0.0%
C:
0.0%
orpathys
lung cancer
china
therapy
cancer
trial
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
Published:
2021-11-01
(Crawled : 06:00)
- globenewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
8.01%
|
O:
-0.12%
H:
1.7%
C:
1.64%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-43.3%
|
O:
-0.07%
H:
3.03%
C:
2.38%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
9.43%
|
O:
-0.3%
H:
0.95%
C:
0.43%
renal
trial
cell carcinoma
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
Published:
2021-09-20
(Crawled : 01:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-56.16%
|
O:
1.1%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
21.53%
|
O:
0.0%
H:
4.33%
C:
4.15%
endocrine
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published:
2021-09-08
(Crawled : 11:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-58.07%
|
O:
-2.29%
H:
1.34%
C:
1.29%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
16.91%
|
O:
-1.85%
H:
0.17%
C:
-0.42%
lung cancer
china
therapy
cancer
trial
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
Published:
2021-07-28
(Crawled : 12:00)
- globenewswire.com
LLY
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
206.57%
|
O:
-0.09%
H:
2.07%
C:
1.29%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-54.24%
|
O:
6.45%
H:
7.99%
C:
7.76%
BGNE
S
|
$131.885
-1.62%
-1.64%
200K
|
Health Technology
|
-50.21%
|
O:
3.23%
H:
13.33%
C:
12.51%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
18.8%
|
O:
-0.75%
H:
0.7%
C:
-0.39%
results
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
Published:
2021-07-28
(Crawled : 01:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-54.24%
|
O:
6.45%
H:
7.99%
C:
7.76%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
18.8%
|
O:
-0.75%
H:
0.7%
C:
-0.39%
cancer
trial
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
Published:
2021-07-13
(Crawled : 07:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-55.47%
|
O:
-0.45%
H:
2.92%
C:
2.12%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
12.83%
|
O:
-0.68%
H:
0.94%
C:
0.87%
china
milestone
commercialization
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
Published:
2021-06-22
(Crawled : 18:00)
- globenewswire.com
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
-36.43%
|
O:
3.66%
H:
1.31%
C:
-4.82%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
17.07%
|
O:
-0.26%
H:
0.28%
C:
-0.46%
lung cancer
china
cancer
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.